A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.

Autor: He, Simon Z.1,2,3 (AUTHOR) simon.he@mh.org.au, Busfield, Samantha4 (AUTHOR), Ritchie, David S.1,2,5,6 (AUTHOR), Hertzberg, Mark S.7,8 (AUTHOR), Durrant, Simon9 (AUTHOR), Lewis, Ian D.10 (AUTHOR), Marlton, Paula11,12 (AUTHOR), McLachlan, Andrew J.13 (AUTHOR), Kerridge, Ian7 (AUTHOR), Bradstock, Kenneth F.7 (AUTHOR), Kennedy, Glen9 (AUTHOR), Boyd, Andrew W.9,12,14 (AUTHOR), Yeadon, Trina M.14 (AUTHOR), Lopez, Angel F.15 (AUTHOR), Ramshaw, Hayley S.15 (AUTHOR), Iland, Harry16 (AUTHOR), Bamford, Simone4 (AUTHOR), Barnden, Megan4 (AUTHOR), DeWitte, Mark4 (AUTHOR), Basser, Russell4 (AUTHOR)
Zdroj: Leukemia & Lymphoma. May2015, Vol. 56 Issue 5, p1406-1415. 10p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje